Oncocyte corp (OCX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
REVENUE
Total revenue

16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

TOTAL COSTS AND OPERATING EXPENSES
Cost of revenues

173

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

2,159

2,318

1,625

1,508

1,343

1,204

1,527

2,322

1,461

1,507

1,836

1,997

1,834

1,430

1,363

1,195

1,689

1,430

1,094

886

1,117

General and administrative

4,625

4,194

3,002

3,636

2,449

2,573

1,312

1,335

1,787

1,785

4,289

1,115

2,043

1,120

1,063

1,067

1,015

1,786

1,312

519

250

Sales and marketing

1,490

1,011

630

318

205

270

184

569

658

601

710

477

655

544

156

270

228

-

-

-

-

Total costs and operating expenses

8,447

7,523

5,257

5,462

3,997

4,047

3,023

4,226

3,906

3,893

6,835

3,589

4,532

3,094

2,582

2,532

2,932

3,540

2,406

1,405

1,367

Loss from operations

-8,431

-7,523

-5,257

-5,462

-3,997

-4,047

-3,023

-4,226

-3,906

-3,893

-6,835

-3,589

-4,532

-3,094

-2,582

-2,532

-2,932

-3,540

-2,406

-1,405

-1,367

OTHER INCOME (EXPENSES), NET
Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

-

-

-

-

Interest expense, net

-22

16

135

167

-19

-50

-50

-56

-60

-68

-71

-65

-13

-

-

-

-

-

-9

-6

-2

Unrealized gain (loss) on marketable equity securities

-53

-36

-103

-88

178

-496

102

-223

190

-

0

0

0

-

-

-

-

-

-

-

-

Pro rata loss from equity method investment in Razor

-329

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of available-for-sale securities and other expenses, net

-

-

-

-

-

-

-

-

-

-

0

-150

-

-

0

0

-

-

-

-

-

Other income (expenses), net

8

22

0

1

-26

95

-2

0

-2

-

-

-

-159

24

-13

-11

0

-

-1

-

-

Total other income (expenses), net

-396

-431

32

79

133

-453

52

-279

128

-68

-71

-215

-172

-8

-13

-11

4

1

-10

-6

-2

LOSS BEFORE INCOME TAXES

-8,827

-

-

-

-3,864

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

1,095

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET LOSS

-7,732

-7,954

-5,225

-5,383

-3,864

-4,500

-2,971

-4,505

-3,778

-3,961

-6,906

-3,804

-4,704

-3,102

-2,595

-2,543

-2,928

-3,539

-2,416

-1,411

-1,369

Net loss per share; basic and diluted

-0.13

-0.16

-0.10

-0.10

-0.08

-0.11

-0.07

-0.12

-0.12

-0.13

-0.22

-0.13

-0.16

-0.10

-0.10

-0.10

-0.12

-0.15

-0.12

-0.07

-0.08

Weighted average shares outstanding; basic and diluted

61

101,191

51,973

51,973

46

40,789

40,227

38,708

31,676

62,386

30

29,398

28,965

28,733

26,560

25,427

25,396

23,666

20,970

21,200

18,200